Preparation, in-vitro and in-vivo characterization of transdermal patch containing glibenclamide and atenolol: A combinational approach

Pakistan Journal of Pharmaceutical Sciences

Volumn 24, Issue 2, 2011, Pages 155-163

  Anitha, Posina ^a   Ramkanth, Sundarapandiyan ^a   Saleem, Mohamed T S ^a   Umasankari, Kommireddy ^a   Reddy, Boddu Praveen ^a   Chetty, Madhusudhana ^a  

^a ANNAMACHARYA COLLEGE OF PHARMACY   (India)

Author keywords

Atenolol; Diabetes; Glibenclamide; Hypertension; Transdermal patches

Indexed keywords

ATENOLOL; CARBOMER; GLIBENCLAMIDE; HYDROXYPROPYLMETHYLCELLULOSE; POLYMER;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; DIFFUSION; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; EVALUATION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHYSICAL CHEMISTRY; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ANIMALS; ATENOLOL; GLYBURIDE; GOATS; MALE; RABBITS; RATS; RATS, WISTAR;

EID: 79953880812     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bhupinder S, Sukhwinder KC, Naveen Ahuja (2006). Formulation and optimization of controlled release mucoadhesive tablets of Atenolol using response surface methodology. AAPS PharmSciTech, 7(1): E1-E10.
2. Biswajit M, Sushmita M, Ritu Guptab (2005). Comparison between povidone-ethyl cellulose and povidone- Eudragit transdermal Dexamethasone matrix patches based on in vitro skin permeation, Eur. Jour. Pharma. Biopharm., 59: 475-483.
3. Chakkapan S, Kiran Gandhi, Suja Thomas, Katkam RR, Puri CP and Srivastava R (1994). Studies in transdermal drug delivery system for estradiol, Indian Jour. Pharma. sci., 56(4): 121-125.
4. Draize JH, Woodard G and Calvery HO (1944). Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. Jour. Pharmacol. Experi. Ther., 82: 377-390.
5. Epstein M and Sowers JR (1992). Diabetes mellitus and hypertension, Hypertension, 19: 403-418.
6. Grundy SM., Benjamin IJ, Burke GL (1999). Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation, 100: 1134-1146. (Pubitemid 29416243)
7. Jagmohan (2003). Organic Spectroscopy. Edn 2, Narosa Publications, Inc., New Delhi, pp.212-232.
8. Jayaprakash S, Mohamed Halith S and Mohamed Firthouse PU (2010). Preparation and evaluation of celecoxib transdermal patches. Pak. Jour. Pharma. Sci., 23(3): 279-283.
9. Ji-Hui Zhao, Ji-Hua Fu and Shu-Ming Wang (2007). A novel transdermal patch incorporating Isosorbide dinitrate with Bisoprolol: In-vitro and In-vivo characterization. Int. Jour. Pharma., 337: 88-101. (Pubitemid 46756040)
10. Ke GM, Wang L, Xue HY, Lu WL, Zhang X, Zhang Q and Guo HY (2005). In-vitro and In-vivo characterization of a newly developed Clonidine transdermal patch for treatment of attention deficit hyperactivity disorder in children. Biol. Pharma. Bull., 28: 305-310. (Pubitemid 40880014)
11. Kroenke K and Pinholt EM (1991). Reducing polypharmacy in the elderly: A controlled trial of physician feedback. Jour. Am. Ger. Soc., 39: 103-105.
12. Kulkurni Raghavendra, Doddaya H, Marihal SC, Patiln CC and Habhu PV (2000). Comparative Evaluation of Polymeric films for Transdermal Application. The East. Pharma., 516: 109-111.
13. Kusum Devi V, Saisivam S, Maria GR and Depti PU (2003). Design and Evaluation of Matrix diffusion Controlled Transdermal patches of Verapamil Hydrochloride. Drug Del. Ind. Pharm., 29: 495-503. (Pubitemid 36597390)
14. Marin EL and Modamio P (1998). Transdermal absorption of celiprolol and bisoprolol in human skin in-vitro. Int. Jour. Pharma., 173: 141-148. (Pubitemid 29027768)
15. Mazzo DJ, Obetz CL, Shuster J and Brittain HG (1994). Analytical profiles of drug substances and excipients. Academic Press Inc., San Diego, CA. 23: 53.
16. McDaid DM and Deasy DM (1996). An investigation into the transdermal delivery of nifedipine, Pharma. Acta. Helv., 71: 253-258. (Pubitemid 26358938)
17. Mundada AS and Avari JG (2009). Damar Batu as a novel matrix former for the transdermal drug delivery: In-vitro evaluation. Drug Del. Ind. Pharm., 35: 1147-1154.
18. Robert J Bloder (2006). Transdermal drug delivery: Time for Closer look, Drug delivery report spring/summer, pp. 27-30.
19. Samanta MK, Dube R and Suresh B (2003). Transdermal drug delivery system of Haloperidol to overcome selfinduced extrapyramidal syndrome. Drug Del. Ind. Pharm., 29(4): 405-415. (Pubitemid 36528608)
20. Srinivas M, Narayana B, Udupa (2005). Formulation development, in-vitro and in-vivo evaluation of membrane controlled transdermal systems of Glibenclamide. Jour. Pharma. Sci., 8(1): 26-38.
21. Srinivas Mutalik, Nayanabhirama Udupa, Sharath Kumar, Sunil Agarwal, Ganesh Subramanian and Averineni K Ranjith (2006). Glipizide matrix transdermal systems for diabetes mellitus: Preparation, in-vitro and preclinical studies. Life Sci., 79: 1568-1577. (Pubitemid 44301274)
22. Ubaidulla U, Reddy MVS, Ruckmani K, Ahmed FJ and Khar RK (2007). Transdermal therapeutic system of carvedilol: Effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics. AAPS PharmSciTech, 8: E 1-8.
23. Udupa N, Koteshwar KB, Vasantha Kumar (1992). Formulation and Evaluation of Captopril Transdermal preparations, Indian Drugs, 29: 680-685. (Pubitemid 23153920)
24. UL Prospective Diabetes Study (UKPDS) Group (1998). Intensive blood glucose control with sulphonyl urea or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes mellitus (UKPDS 33). Lancet, 352: 837-853.
25. Vivian F, Ali Jawa, Senthil N, Merri P, Sunil A (2008). Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. Jour. Diab. Compli., 22: 303-308.
26. Vlassios A, Mounir S. Mesiha (1995). Design and evaluation of transdermal Chlorpheniramine maleate drug delivery system. Pharma. Acta. Helv., 70: 301-306. (Pubitemid 26156932)
27. Yanli Gao and Jinying Liang (2009). Double-layer weekly sustained release transdermal patch containing gestodene and ethinylestradiol. Int. Jour. Pharma., 377: 128-134.